PREAMBLE
The following formulary applies to all A.R.N.P.'s licensed in the State of New Hampshire. It is developed and approved by the Joint Health Council. This revision, dated March 2004, replaces all previous formularies.
The following applies to this formulary:
1. It is an exclusionary formulary; i.e., if a drug is NOT listed, it is approved for use within an A.R.N.P.'s scope of practice.
2. There are two columns: the first, a list of drugs alphabetically by generic name; the second, a column marked "Exceptions" which further clarifies any restrictions or requirements.
3. If a drug is listed in the first column and there are no clarifications in the second column, that drug is totally restricted for A.R.N.P. use.
a. Example: apraclonidine ophthalmic. This drug is listed in the first column. Therefore it is restricted for A.R.N.P. use. The second column is blank. Thus, there are no exceptions to that restriction. The restriction is total.
4. If a drug is listed in the first column, it is restricted unless that restriction is modified or clarified in the second column (i.e., an "exception" to that restriction.)
a. Example: alprostadil. This drug is listed in the first column. Therefore it is restricted for A.R.N.P. use. The second column notes: "Permitted with physician consultation." Thus, although this drug is restricted, it is permitted with physician consultation, within the A.R.N.P.'s scope of practice. The restriction is not total, as with the example in (3) above.
5. For combination drugs with more than one active ingredient, if one ingredient is restricted, the entire combination drug is restricted.
6. If a drug is restricted to "renewal of physician initiated prescription," the A.R.N.P. must write the letter "R" on the face of the prescription or the order sheet.
DEFINITIONS
1. CONSULTATION: Consultation is defined as written communication with a practitioner who has expertise in the pharmacologic management of a particular patient condition. The written communication shall appear in the patient's medical record. (Revised 11/28/05).
2. COLLABORATION: Collaboration is defined as a discussion or other mode of communication between the ARNP and another practitioner who has expertise in the pharmacological management of a particular patient condition. This requirement may be satisfied by the use of specific group protocol or established practice parameters. (Revised 11/28/05).
3. PHYSICIAN: A Doctor of Medicine or Doctor of Osteopathy currently licensed in 1 of the 50 United States.
4. INSTITUTION: Institution is defined as a health care facility that provides in-patient care and includes hospitals, nursing homes, extended care facilities, residential care facilities, infirmaries and clinics.
5. PARENTERAL: Parenteral means by injection (intradermal, subcutaneous, intramuscular, intravenous, or per non-enteral catheter.)
6. RENEWAL OF PHYSICIAN INITIATED PRESCRIPTION: Renewal of a physician initiated prescription without change in dose. |
